Journal
CURRENT OPINION IN CHEMICAL BIOLOGY
Volume 6, Issue 4, Pages 472-478Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/S1367-5931(02)00342-3
Keywords
-
Categories
Ask authors/readers for more resources
With taxanes continuing to prove useful in the clinical treatment of cancer, the next generation of antimitotic agents has entered clinical trials. Other mechanisms awaiting proof-of-concept for the treatment of antiproliferative diseases include inhibition of cyclin-dependent kinases (Cdks). Flavopiridol and UCN-01 are continuing in clinical trials, and newer more selective Cdk inhibitors are now entering clinical evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available